The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial
Abstract
Rituximab is a B cell‐depleting anti‐CD20 chimeric IgGK monoclonal antibody being investigated for the treatment of rheumatoid arthritis. The purpose of this study was to develop a population pharmacokinetic model in rheumatoid arthritis patients. In addition, the final pharmacokinetic model was used to assess the variability in drug exposure (AUC 0‐∞) for fixed versus body surface area‐based dosing. A total of 102 patients were included in this population pharmacokinetic analysis. A 2‐compartment pharmacokinetic model described the data reasonably well. Body surface area and gender were the most significant covariates for both CL and Vc. Body surface area alone only explained about 19.7% of the total interindividual variability of CL. In a simulation study, body surface area‐based dosing normalized drug exposure over a wide range of body surface area but did not seem to improve the predictability of rituximab AUC 0‐∞ in rheumatoid arthritis patients. Therefore, no rationale for body surface area‐based dosing for rituximab in rheumatoid arthritis patients was found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
Pescovitz, M. D. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01288.x · Cited by 625
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Jones, R. B., Ferraro, A. J., Chaudhry, A. N., Brogan, P., Salama, A. D., Smith, K. G. C., Savage, C. O. S., & Jayne, D. R. W. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24637 · Cited by 350
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Fasanmade, A. A., Adedokun, O. J., Ford, J., Hernandez, D., Johanns, J., Hu, C., Davis, H. M., & Zhou, H. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0718-4 · Cited by 327
Metadata
- Authors
- Ng, C. M., Bruno, R., Combs, D., & Davies, B.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-07
- Volume
- 45
- Issue
- 7
- Pages
- 792-801
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2163032035
- Cited by
- 203
- References
- 1
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial. https://app.cochat.ai/papers/10.1177/0091270005277075
- The paper
- Ng, C. M., Bruno, R., Combs, D., & Davies, B. (2005). Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270005277075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.